Gland Pharma is investing $21 million to acquire a 60% stake in the newly formed US company, Novelstar Pharma. The deal, set to close by October 31, 2026, is part of a plan to expand operations in the American market. Investors are noting the risks tied to the startup nature of the new entity, alongside recent changes in the company’s board of directors.
Gland Pharma has announced a plan to invest $21 million to acquire a 60% controlling stake in Novelstar Pharma, a newly formed entity based in the United States. The transaction, which involves a related party, is expected to conclude by October 31, 2026. Fosun Pharma USA, an affiliate entity, will hold the remaining 40% of the venture. This capital injection is intended to increase Gland Pharma's reach in the competitive US pharmaceutical market.
Execution Risk and Deal Structure
The investment carries a specific business risk that shareholders may note: Novelstar Pharma is a newly incorporated firm and currently has no operational history or existing revenue. This means the company’s success in this venture relies entirely on building the business from the ground up, rather than integrating an established company. As a related-party transaction—since the other stake is held by a promoter group affiliate—the deal is subject to regulatory oversight to ensure it is conducted at arm’s length. Investors will likely track how quickly this new entity can generate revenue and whether it can navigate the complex US generic drug landscape, which has seen price pressures recently.
Leadership Changes and Board Updates
Alongside the US expansion news, Gland Pharma disclosed a change in its governing board. Non-executive, non-independent director Wenjie Zhang resigned from the position on October 1, 2026, citing other professional commitments. To fill the vacancy, the board appointed Xingli Wang, who currently serves as the president of Fosun Pharma. Wang brings experience from global pharmaceutical companies such as Novartis and Schering-Plough. This appointment is subject to formal ratification by shareholders through a postal ballot and e-voting process. Additionally, Dr. Jia Ai Zhang has been appointed to the company’s Stakeholders' Relationship and Share Transfer Committee.
Market and Stock Reaction
On the stock exchanges, the market reaction to the twin developments—the US investment and the board reshuffle—was muted. Gland Pharma shares ended the trading session on October 1, 2026, at ₹2,866, marking a decline of 1.15% for the day. For investors, the most critical monitorable in the coming months will be the progress of Novelstar Pharma’s operational setup and whether the company can successfully scale its US business to offset the capital spent on this new venture.